Sign in
4

Changes in Ownership

Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-046731

Chief Accounting Officer sold 1,653 shares at $2.50 ($4,125)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hagen Brett R · Chief Accounting Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2023-08-17 Sale : show line 1 in the form 10b5-1 −1,653 $2.50 $4,125 127,175 D
Open-market sales · 1,653 sh · avg $2.50 · $4,125
Loading xslF345X05/doc4.xml…